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Anaplastic Large Cell Lymphoma 




Breast implant-associated anaplastic large cell lymphoma is a rare disease first 
described in 1997. Since then, its incidence has continued to increase. Current 
estimated lifetime risk in women with textured breast implants range from 1:1000 
to 1:30,000. Most cases present with rapid and dramatic breast swelling resulting 
from peri-implant fluid collection. Palpable mass, pain, and skin lesions also occur. 
A high index of suspicion in patients who develop a seroma around the breast 
implant more than one year after implant placement is required. The combination 
of clinical history, physical exam findings, and appropriate imaging workup can 
lead to a timely and accurate diagnosis. The disease has excellent prognosis when it 
is diagnosed earlier, and complete surgery is performed. Radiologists, particularly 
those involved in breast imaging, can play an essential role in early diagnosis. This 
chapter presents an overview of the disease, including relevant imaging findings.
Keywords: breast implant-associated anaplastic large cell lymphoma, epidemiology, 
pathophysiology, diagnosis, treatment, prognosis, mammography, ultrasound, 
magnetic resonance imaging, fine needle aspiration, needle biopsy,  
positron emission tomography
1. Introduction
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare 
disease first described in 1997 when Keech & Creech published the first case report 
of anaplastic T-cell lymphoma in proximity to a saline-filled breast implant [1]. 
Following the initial report, additional case reports and case series of this entity 
have been published [2–4].
A possible association between breast implants and anaplastic large cell  
lymphoma was announced by the Food and Drug Administration (FDA) in 2011 
[5], and in 2016, the World Health Organization (WHO) added BIA-ALCL as a 
provisionally recognized lymphoma to the family of existing ALCL [6].
In 2019 the FDA issued a safety communication stating, “all individuals who 
are considering a breast implant of any type be informed of the risk of developing 
BIA-ALCL”. At the time, most cases of BIA-ALCL were reported to have Allergan’s 
Biocell textured breast implants, thus, following an FDA recommendation, Allergan 
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initiated a worldwide voluntary recall of their breast implant products in July 
2019 [7].
The incidence of the disease has continued to increase with current estimates 
of the absolute risk for development of BIA-ALCL ranging from 1 in 3,817 to 1 in 
30,000 [8].
BIA-ALCL is characterized by the development of peri-implant fluid collection 
that occurs >1 year after breast implant placement, and/or by a solid mass arising 
within the implant’s fibrous capsule [9]. Median time since implant placement at 
diagnosis is estimated at 8–10 years [9].
Overall, the disease has an excellent prognosis, particularly if diagnosed and 
fully treated at early stage [10]. It is therefore important to increase awareness about 
this disease amongst health care providers in general and amongst radiologists 
and provide them with the relevant information for early diagnosis, referral, and 
treatment.
2. Etiopathogenesis
Although the etiology of BIA-ALCL remains poorly understood, there is evidence 
demonstrating a preponderance of patients with BIA-ALCL to have been exposed 
to textured breast implants, developed in the 1980s to reduce implant contractures, 
which in turn provides clues as to the pathogenesis of this condition [11, 12].
Texturing of the implant shell may lead to a greater inflammatory response 
of the surrounding fibrous tissue capsule eliciting an increased chronic antigenic 
stimulation, which in turn could potentially be responsible for the development 
of ALCL [12]. Other potential causes of chronic inflammation which have been 
postulated include lipopolysaccharide endotoxin, trauma to the breast pocket, viral 
infection, and allergens [13].
Currently, there is not enough data to determine whether ALCL may be found 
more or less frequently in individuals with silicone-filled breast implants compared 
to individuals with saline-filled breast implants [14].
The presence of germline and somatic mutations, which can increase the suscep-
tibility of the host to BIA-ALCL has been postulated as a contributing factor [12].
Recent molecular studies have identified novel, activating mutations in the Janus 
kinase (JAK), and signal transducer and activator of transcription factor (STAT3) 
pathway as a major risk factor for the development of BIA-ALCL (the presence of 
germline and somatic mutations, which can increase the susceptibility of the host 
to BIA-ALCL). Aberrant STAT3 signaling has been established as a mechanistic link 
between chronic inflammation in non–BIA-ALCL cancers, including B- and T-cell 
lymphomas, and amongst the latter systemic anaplastic large cell lymphomas (the 
presence of germline and somatic mutations, which can increase the susceptibility 
of the host to BIA-ALCL) and persistent STAT3 activation has been definitively 
linked to improved tumor survival and cell proliferation, increased angiogenesis, 
and tumor metastasis [13].
3. Epidemiology
Current estimates suggest that each year over 1.8 million people worldwide 
receive breast implants for cosmetic or reconstructive purposes [15]. In July of 2019 
the number of BIA-ALCL reported cases worldwide reached 573, with 320 those 
cases reported in the US [16]. The estimated lifetime risk of BIA-ALCL in women 
with textured breast implants range from 1:1,000 to 1:30,000 [17]. A reported 
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geographic variation of the risk is likely due to variable reporting and less likely to 
geographic or genetic predisposition [17].
4. Clinical features
Mean age at diagnosis is 53.2 ± 12.3 years [17]. Mean interval from implant 
placement to diagnosis is 10.7 ± 4.6 years [17]. However, this late-onset diagnoses 
may reflect delayed diagnosis or misdiagnosis.
Patients most commonly present with rapid onset of a spontaneous fluid  
collection (60–90%) or capsular mass (10–40%) [9]. Approximately 30% of 
patients report pain, and about 25% present with skin lesions, most commonly 
erythema, subcutaneous nodules, eruption, erosion, or ulcer [9].
Implant capsule contracture is present in approximately 30% of cases [9]. When 
this occurs, there is a preponderance of grade III and IV contracture, defined as 
clinically symptomatic and visible contracture of the implant capsule [18].
BIA-ALCL disseminates locally in a small proportion of cases [19]. When 
local dissemination takes place it most commonly involves the ipsilateral axillary 
lymph nodes [19]. The prevalence of lymphadenopathy at diagnosis ranges from 
2–14% [19].
Distant disease is uncommon. There are case reports of and distant lymph nodes 
and bone marrow involvement [19]. Systemic symptoms, such as unexplained 




In general, mammography findings include nonspecific capsular thickening, and 
circumferential asymmetry around the implant (Figures 1 and 2) [19, 20].
Figure 1. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Bilateral digital mammogram shows bilateral retro glandular saline 
breast implants. The right breast is larger than the left and shows a homogeneous and circumferential area 
of increased density (arrow) surrounding the implant, including the area of palpable abnormality noted by 




63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Grey scale ultrasound shows right breast peri-implant fluid collection 
(arrow) (source: Collado-Mesa et al. [20]).
Unlike with primary breast cancer, mammography is not accurate for detection 
of either peri-implant effusion or mass-forming BIA-ALCL.
Overall, mammography has a lower sensitivity and specificity than both ultra-
sound and Magnetic Resonance Imaging (MRI) for any abnormality due to BIA-
ALCL, at 73% and 50% respectively [21].
5.2 Ultrasound
Ultrasound (US) is the imaging exam of choice. Findings most commonly 
include a homogeneous peri implant effusion with inflammatory changes in the 
periprosthetic breast tissue (Figures 3 and 4).
Figure 2. 
54-year-old female status post left breast mastectomy for DCIS and right breast prophylactic mastectomy, 
followed by immediate bilateral breast silicone implant with textured surface reconstruction 11 years ago 
presented with sudden onset of right breast swelling and enlargement with associated discomfort. She denied 
fever or general symptoms. Bilateral mammogram shows irregular contours of the right breast silicone implant 
with associated focal-peri-implant increased density (arrows) (source: Collado-Mesa et al. [20]).
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When a solid mass is present, it frequently appears as an oval, hypoechoic, 
circumscribed mass, without hypervascularity (Figure 5) [19, 20]. Less frequently, 
it appears as a complex cystic and solid mass [19, 20].
Some cases may present with abnormal ipsilateral axillary lymph nodes, includ-
ing the presence of nodal cortical thickening or diffusely hypoechoic without 
evident fatty hilus.
Amongst the commonly used breast imaging modalities, the highest sensitivity 
for detection of peri-implant fluid collection is reported for ultrasound (84%) [21]. 
Ultrasound is also reported to have the highest specificity for detection of solid 
mass (100%) [21].
Figure 4. 
Effusion-only BIA-ALCL in a 55-year-old woman after mastectomy for breast cancer. The initial breast 
implant was exchanged after 9 years; 7 years later, she experienced sudden new marked implant-associated 
swelling. Transverse US image shows a large seroma with septa surrounding the intact implant (arrow). 
US-guided fine-needle aspiration yielded cloudy yellow fluid, cytologic analysis of which demonstrated ALK-
negative BIA-ALCL (source: Sharma B et al. [19]).
Figure 5. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Grey scale ultrasound shows a 4 × 1.4 × 2.4 cm mixed echogenicity, oval, 
partially, indistinct mass (arrow) abutting the fibrous capsule in the right breast at 7 o’clock, 5 cm from the 
nipple, corresponding to palpable abnormality (source: Collado-Mesa et al. [20]).
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5.3 Magnetic resonance imaging
Breast Magnetic Resonance Imaging (MRI) is the imaging test of choice after 
US, and it particularly add value when US results are indeterminate.
MRI findings include peri-implant tissue edema and effusion, as well as peri-
implant mass lesions, including small-volume mass components not detected with 
US. Enhancement with intravenous gadolinium contrast material may also help 
with characterization of some findings (Figures 6–10) [19, 20].
MRI also serves to evaluate for the presence of implant rupture when there is a 
silicone implant [19].
MRI is the imaging modality with the second highest sensitivity for peri-
implant fluid collection at 82% and with the second highest specificity for mass 
at 93% [21].
Figure 7. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Breast MRI axial T1-weighted fat saturated postcontrast subtraction shows 
a 4 × 1.7 × 2 cm oval heterogeneously enhancing mass (arrow) arising from the fibrous capsule in the right 
lower outer quadrant (source: Collado-Mesa et al. [20]).
Figure 6. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Breast MRI axial T2-weighted fat-saturated sequence shows right breast 
peri-implant fluid collection (arrow) (source: Collado-Mesa et al. [20]).
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Figure 8. 
Mass forming BIA-ALCL in a 29-year-old woman with a right upper inner breast mass 3 years after bilateral 
breast augmentation with TRF-520 implants (Allergan). Axial gadolinium enhanced fat-saturated breath-hold 
volume MR image shows a large implant-associated lobulated mass with a central necrotic area and intense 
rim enhancement (arrow) infiltrating the pectoralis major muscle and threatening the intercostal muscles. 
Biopsy demonstrated BIA-ALCL (source: Sharma B et al. [19]).
Figure 9. 
BIA-ALCL with chest wall invasion in a 29-year-old woman who underwent bilateral breast augmentation 
with TRF-520 implants (Allergan) and developed a right upper inner breast lump 3 years after surgery. Axial 
fast spin-echo T2-weighted image with breath holding 4 months later shows irregular surface of the implant 
(blue arrow) and rapid enlargement (estimated at 7 cm axially) of the lobulated mass (red arrow), which is 
characterized by a central necrotic area. Biopsy demonstrated large atypical CD30-positive cells infiltrating the 
fibrous tissue. The final diagnosis was BIA-ALCL (source: Sharma B et al. [19]).
Figure 10. 
BIA-ALCL with chest wall invasion in a 29-year-old woman who underwent bilateral breast augmentation 
with TRF-520 implants (Allergan) and developed a right upper inner breast lump 3 years after surgery. 
Sagittal short τ inversion-recovery (STIR) image obtained 4 months later shows the mass (arrow) infiltrating 
the pectoralis major muscle and threatening the intercostal muscles. Biopsy demonstrated large atypical CD30-
positive cells infiltrating the fibrous tissue. The final diagnosis was BIA-ALCL (source: Sharma B et al. [19]).
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6. Diagnosis and histologic features
A high index of suspicion of BIA-ALCL is required to allow a timely diagnosis.
Breast ultrasound should be obtained in patients with suspicious signs and 
symptoms such as breast swelling, palpable mass, pain, and skin lesions which have 
developed more than one year after implant placement (average 8–10 years).
If a peri-implant effusion is noted, then fine needle aspiration of at least 50 ml 
should be performed [22]. In cases where a peri-implant mass is present, either core 
needle biopsy or surgical excisional biopsy should be performed [22].
In cases with inconclusive findings on ultrasound, a breast MRI should be 
obtained [22].
Figure 11. 
Photomicrograph of ultrasound-guided core needle biopsy samples of solid mass showed in Figure 5 shows 
most of the cells to be strongly and uniformly positive for CD30 (CD30 immunohistochemistry, ×60) (Source: 
Collado-Mesa et al. [20]).
Figure 12. 
Effusion-only BIA-ALCL in a 55-year-old woman after mastectomy, axillary node dissection, implant 
reconstruction, chemoradiotherapy, and immunotherapy. After 9 years, the implant was exchanged; 7 years 
later, sudden new marked swelling of the right breast developed. At US, a large seroma surrounded the 
intact right breast implant; diagnostic aspirate yielded cloudy yellow fluid, which was ALK-negative at 
cytologic analysis. Immunohistochemistry slides show that the infiltrate is positive for CD30 (source: Sharma 
B et al. [19]).
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Samples should be sent for cytology, flow cytometry, immunohistochemistry for 
CD30 (Figures 11 and 12) and additional differentiation markers (CD2 – CD5, CD7, 
CD8, CD45, and ALK [19, 20, 22].
The presence of large neoplastic cells that have pleomorphic nuclei, abundant 
eosinophilic cytoplasm, and irregular cell membranes is required for diagnosis 
(Figure 13). Uniform CD30 expression, evidence of a single T-cell clone, and an 
absence of ALK expression are also observed [22]. Epithelial membrane antigen 
(EMA) is also often expressed by neoplastic cells [23]. “Hallmark cells” with eccen-
tric kidney or horseshoe-shaped nuclei are not uncommonly seen [23].
If results are indeterminate, a referral to a cancer center is recommended. If 
results are negative, then it should be treated as a benign seroma. Patients with posi-
tive results require a disease workup [22].
7. Staging
The traditional staging for all lymphoma is the Ann Arbor classification. 
However, BIA-ALCL is not a classical non-Hodgkin lymphoma and it usually prog-
ress locally and/or regionally like a solid tumor; thus, it is better suited to the TNM 
system for staging solid tumors.
Figure 13. 
Photomicrograph of ultrasound-guided core needle biopsy samples of solid mass showed in Figure 5 shows large 
and pleomorphic neoplastic cells with irregular nuclei, large prominent nucleoli, conspicuous mitotic activity, 
and moderate cytoplasm (hematoxylin and eosin [H&E], ×60) (source: Collado-Mesa et al. [20]).
TNM Criteria
T: Tumor extent
T1 Confined to effusion or a layer on luminal side of capsule
T2 Early capsule infiltration
T3 Cell aggregates or sheets infiltrating the capsule
T4 Lymphoma infiltrates beyond the capsule
N: Lymph node
N0 No lymph node involvement
N1 One regional lymph node involved
N2 Multiple regional lymph nodes involved
Lymphoma
10
The 2019 update of the National Comprehensive Cancer Network guidelines 
now include a TNM disease staging system based on clinical and pathological 
evaluation first proposed in 2016 by MD Anderson Cancer Center and which may 
be more applicable for predicting a prognosis and for evaluating treatment  
regimens in patients with BIA-ALCL [22].
In this TNM classification for BIA-ALCL the disease is considered extended 
(not localized) if there is tumor invasion beyond the fibrous capsule, spread 




A surgical oncology consultation is not compulsory but may be beneficial for 
plastic surgeons unaccustomed to optimal surgical resection of a malignancy.
The goals of surgery are to remove the implant with the surrounding fibrous 
capsule and any associated capsule mass. Complete surgical excision prolongs 
both overall survival and event-free survival compared with all other therapeutic 
interventions [10].
All attempts should be made to gain complete surgical resection because 
retained or unresectable disease likely indicates the need for adjuvant treatments.
An estimated 2–4% of patients develop bilateral disease, and therefore surgeons 
may consider removal of the contralateral implant and capsule [10].
Currently, there is no clear role for radical mastectomy or sentinel lymph node 
biopsy. Full axillary dissection has been used rarely for gross involvement of 
multiple lymph nodes.
8.2 Adjuvant treatments
No data from prospective trials is available to guide management of patients 
with disseminated BIAS-ALCL. Current treatment is based on experiences from 
treating primary cutaneous and systemic ALCL.
TNM Criteria
M: Metastasis
M0 No distant spread








IV T(any) N(any) M1
Modified from source: (Clemens et al. [22]).
Table 1. 
TNM stage classification of BIA-ALCL.
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Radiation therapy with 24–36 Gray (Gy) to the local or involved site is suggested 
for patients with local residual disease, positive margins, or unresectable disease 
with chest wall invasion [22].
Systemic therapy for patients with stage IIB-IV disease can be as combination 
anthracycline based chemotherapy or as a combination with brentuximab vedotin [22].
9. Surveillance and prognosis
In patients with complete response to treatment, surveillance should include 
history and physical exam and either a CT chest, abdomen, and pelvis with  
contrast or a whole-body PET-CT every 6 months for two years and then as clini-
cally indicated (Figures 14 and 15) [22].
BIA-ALCL has shown to have an excellent prognosis when the disease is diagnosed 
earlier (localized disease), and when complete surgery, consisting of explantation, 
capsulectomy, and removal of any associated capsule mass, is performed [9, 10].
Compared to stage I disease, stage II and stage III disease have a rate of  
disease events and recurrence which are 2.6-fold higher and 2.7-fold higher 
respectively [10].
Patients with T1–T3 disease have 0% rate of disease events following complete 
surgical excision as compared to T4 disease have a 14.3% in patients with T4 
disease [10]. Local recurrence is most common if incomplete resection or partial 
capsulectomy took place [10].
A study of causes of death in patients diagnosed with BIA-ALCL showed that all 
the patients who died had incomplete surgical excision or did not receive targeted 
therapy [24]. The study also reported delay in diagnosis or treatment for an average 
of 1–2 years [24]. Direct extension into the chest wall leading to respiratory failure 
was a common cause of death [24]. Other less commonly reported causes of death 
included stem cell transplant complication and development of a second unrelated 
lymphoma [24].
Figure 14. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Screen capture of a whole body 18F-FDG PET/CT shows FDG activity of 
SUV 10.56, corresponding to a soft tissue mass (arrow) in the lower outer quadrant of the right breast adjacent 




In the absence of infection or trauma, the development of a new peri-implant 
effusion more than one year after breast implant placement should prompt consid-
eration for the diagnosis of BIA-ALCL As the clinical symptoms are often nonspe-
cific, radiologists, particularly those involved in breast imaging, play an important 
role in its diagnosis,. While mammography may demonstrate subtle abnormalities, 
ultrasound and MRI have higher sensitivity and specificity. Diagnosis requires 
sampling of peri-implant fluid or mass and or lymph node. Suspicion of BIA-ALCL 
should be communicated to the pathologist, and immunohistochemistry for CD30 
ordered. Once diagnosed, oncology referral and multi-specialty team care includ-
ing plastic surgery and radiation therapy is recommended. Prompt diagnosis and 
complete treatment appear to lead to excellent prognosis.
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Figure 15. 
63-year-old female with history of saline breast implants with textured surface placed 19 years ago presented 
with pain and swelling throughout the right breast and a palpable abnormality in the posterior third of the 
right breast at 7 o’clock for 1 month. Screen capture of a whole body 18F-FDG PET/CT obtained 6 months after 
bilateral breast explantation and total capsulectomy shows no abnormality (source: Collado-Mesa et al. [20]).
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